PAB - I hold lease Patrys Quarterly Activities Report and Appendix 4C Melbourne, Australia; 30 July 2020: Patrys (ASX: PAB, “Patrys” or the Company), a therapeutic antibody development company, is pleased to announce further progress across its Deoxymab platform (including PAT-DX1 and PAT-DX1-NP) and the release of its Appendix 4C for the quarter ended 30 June 2020. Key highlights • Appointment of Dr. Peter Ordentlich to Scientific Advisory Board to strengthen skill base as Patrys moves towards anticipated Phase 1 study • Patrys collaborators have been awarded Lion Heart Fund for Cancer Research grant of US$50,000; US National Institutes of Health (NIH) R01 grant of US$1.83m; and Department of Defence (DoD) grant of US$1.95m, to support ongoing work in the areas of glioblastoma (GBM) and breast cancer metastases • Announcement of fully underwritten, non-renounceable rights issue to raise approximately A$4.29 million before costs supported by two of Patrys’ largest shareholders • Cash at bank at close of quarter of A$3.98m and net cash outflows of A$619k including A$411k invested in R&D activities Operations
